Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2016

View Archived Issues

AS03-adjuvanted GlaxoSmithKline H7N9 pandemic influenza vaccine induces robust antibody responses

REDUCE-IT study of Amarin's Vascepa to continue as planned

Medicines for Malaria Venture initiates first-in-human trial of P-218

Circle Pharma and Pfizer enter agreement to build screening library of macrocyclic peptides

Bioblast Pharma reports results from extension study of trehalose in OPMD

Voyager Therapeutics enters collaboration to advance VY-HTT01 program

Semma Therapeutics receives grant for personalized cell therapy for diabetes

Phase II study of Flex Pharma's FLX-787 in ALS begins

FDA awards fast track designation to Aptinyx's NYX-2925

Ligand Pharmaceuticals initiates phase II study of LGD-6972

AmpliPhi Biosciences's AB-SA01 well tolerated in phase I study

Oxford Gene Technology launches new FISH probes for lung cancers

MMRF and Memorial Sloan Kettering collaborate on minimal residue disease trial

ANA positivity combined with anti-DFS70 negativity may be associated with CTD in NSIP patients

Dual GLP-1R/glucagon receptor agonist MOD-6031 enters phase I development for obesity

Morphotek and Fox Chase Cancer Center enter research agreement

European Commission approves Cabometyx for advanced renal cell carcinoma

CDRD launches new company developing novel rapid sepsis diagnostic

Cellectar Biosciences' CLR-131 to be evaluated in head and neck cancers

BioChaperone Combo reduces postprandial glucose and hyperglycemia risk in type 1 diabetes

MicroRNA 132 can be targeted to improve pressure-induced heart failure

Nanobiotix files for approval of NBTXR-3 in Europe

Hexanal shows potential as an inflammation biomarker

Bayer's emodepside granted U.S. orphan status for onchocerciasis

5-HETE and 5-oxoETE show potential for OSA screening

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...